Aequus Pharmaceuticals IncTSXV:AQSView on OTCQB
- LAST PRICE0.0150
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0100/ 1,539
- Ask / Lots0.0150/ 50
- Open / Previous Close0.0150 / 0.0150
- Day Range
- 52 Week Range
- Volume50,000
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AQS |
|---|
Yesterday
Aequus Provides General Update and Fiscal 2023 Financial Results, from 22 hours ago by Dow Jones
22 hours ago by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aequus Pharmaceuticals Inc | 2.0M | -0.6x | --- |
Silo Wellness Inc | 1.4M | -0.1x | --- |
Vitality Products Inc | 2.3M | -6.4x | --- |
Manitex Capital Inc | 2.1M | 2.6x | +16.92% |
Lumiera Health Inc | 844.0K | -0.4x | --- |
Lucy Scientific Discovery Inc | 1.4M | -0.9x | --- |
Company Information
Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company focused on developing, advancing, and promoting differentiated products. The Company is engaged in the sale and marketing of several commercial products in ophthalmology and transplant. Its pipeline products include Evolve Intensive Gel, Evolve Daily Intensive, SCOPE Portfolio, Zimed PF and REV-0100 / ReVision. Evolve Intensive Gel and Evolve Daily Intensive contains lubricating eye drops intended for use in the relief of discomfort that arises from dry eye sensations, including dryness, soreness, feelings of grit, and irritation. Zimed PF is a preservative-free multi-dose Bimatoprost for glaucoma patients in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. It plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license.
Contact Information
- Headquarters
- 595 Burrard Street, Suite 2600VANCOUVER, BC, Canada V7X 1L3
- Phone
- 604-336-7906
- Fax
- 604-336-7906
Executives
- Chairman of the Board, President, Chief Executive Officer
- Douglas Janzen
- Chief Financial Officer, Corporate Secretary
- Ann Fehr
- Chief Commercial Officer
- Grant Larsen
- Director
- Christopher Clark
- Director
- Anne Stevens
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.0M |
|---|---|
Revenue (TTM) | $587.1K |
Shares Outstanding | 132.6M |
Aequus Pharmaceuticals Inc does not pay a dividend. | |
Beta | 0.26 |
EPS | $-0.02 |
Book Value | $-0.01 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 3.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -557.95% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
